India Boosts Biopharmaceutical Sector with Entrepreneurial Support
The Government of India is taking significant strides to foster entrepreneurship and bolster indigenous manufacturing in the biopharmaceutical sector. Through strategic initiatives and funding, the Department of Biotechnology (DBT) is nurturing a vibrant startup ecosystem, particularly in healthcare, pharmaceuticals, and biopharmaceuticals.
Since its inception in 2012, the Biotechnology Industry Research Assistance Council (BIRAC) has operated as a not-for-profit organization to enhance innovation. It provides grants and support to startups and SMEs, aiming to bridge the funding gap for early-stage biopharmaceutical innovations. The flagship funding initiatives launched by BIRAC, such as the Biotechnology Ignition Grant (BIG) and the Social Innovation Programme for Products: Affordable & Relevant to Societal Health (SPARSH), have successfully supported nearly 1,000 startups. SPARSH alone has facilitated over 150 fellowships, leading to the creation of more than 100 startups and 65 intellectual properties.
Creating a Thriving Biotech Innovation Ecosystem
In its mission to fortify India’s biotechnology landscape, BIRAC has established a robust network of 94 incubators across 25 states and union territories, nurturing over 3,000 incubates and fellows. The BioNEST and E-YUVA schemes are pivotal in promoting entrepreneurship and translational research, offering aspiring innovators a platform to scale their projects.
Additionally, the National Biopharma Mission (NBM), a government-approved initiative, aims to spur discovery research and facilitate early-stage development in biopharmaceuticals. Implemented through BIRAC, this program focuses on the rapid development of vaccines and therapeutics in response to public health needs. Notable achievements under the NBM include the development of two COVID-19 vaccines, the first indigenous MRI scanner, and various diagnostic tools.
Advancing Biomanufacturing Capacities
In a milestone move, the DBT plans to roll out the BioE3 policy in 2024, which focuses on enhancing high-performance biomanufacturing across identified thematic areas. This initiative will establish biofoundries and biomanufacturing hubs in the country, promoting the local production of cutting-edge treatments like monoclonal antibodies and mRNA therapies.
Complementing these efforts, the Department of Pharmaceuticals has introduced a Production Linked Incentive (PLI) scheme, with a budgetary allocation of ₹15,000 crores. This initiative aims to elevate India’s manufacturing capabilities and accelerate production in the pharmaceutical sector, including biopharmaceuticals. As of September 2025, the PLI scheme has facilitated the production of 46 biopharmaceutical products, generating cumulative sales of ₹26,832 crores, including significant exports.
Supporting Agricultural Biopharma Innovations
The Indian Council of Agricultural Research (ICAR) is also playing a key role in advancing biopharmaceutical manufacturing. Through institutions like the National Institute of High Security Animal Diseases (NIHSAD) and the Indian Veterinary Research Institute (IVRI), ICAR develops critical vaccines and diagnostics while supporting livestock biopharma startups with financial grants and R&D infrastructure.
These initiatives highlight the Indian government’s dedication to fostering a supportive environment for biopharmaceutical innovation and entrepreneurship, setting the stage for a more self-reliant and competitive industry.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
